ARTICLE | Product Development
A guide to COVID-19 vaccine modalities in the clinic
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
May 9, 2020 4:32 AM UTC
Updated on May 11, 2020 at 9:30 PM UTC
Of the more than 90 vaccines in development for COVID-19, at least nine -- spanning nucleic acid, viral vector-based and inactivated vaccines -- are in clinical testing.
During infection with SARS-CoV-2, the host proteins ACE2 and TMPRSS2 mediate entry of the virus into the cell by binding the virus’ spike protein, which has emerged as the principal target for vaccination strategies. The host proteins are also targets of at least five therapeutic programs. ...